NorthStar Medical Technologies

NorthStar Medical Technologies is a pioneering radiopharmaceutical company specializing in the non-uranium, accelerator-based production of therapeutic radioisotopes, notably Ac-225 and Cu-67. Its integrated campus houses the technology, facilities, and expertise to serve as a critical CDMO/CMO, addressing supply chain challenges in the rapidly growing targeted radioligand therapy field. The company is positioned as a near-term commercial-scale producer of these high-demand isotopes, supported by strategic partnerships and a pipeline of development programs aimed at expanding treatment options for various cancers.

Non-reactor based production of radioisotopes using electron beam accelerators for environmentally preferred, scalable supply of therapeutic isotopes (e.g., Ac-225, Cu-67). Integrated CDMO/CMO services for radiopharmaceutical development and cGMP manufacturing.

NorthStar competes with other radioisotope producers, including reactor-based suppliers (e.g., NRG, IRE), cyclotron-based producers, and other companies developing alternative Ac-225 production methods. It also competes with large pharmaceutical CDMOs expanding into radiopharmaceuticals. Its key differentiators are its integrated, non-uranium accelerator platform and its full-service CDMO capabilities.